share_log

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A: Preliminary proxy statements relating to merger or acquisition

PRE 14A：并购重组委托声明
美股SEC公告 ·  10/29 16:49

Moomoo AI 已提取核心信息

180 Life Sciences Corp., a Delaware corporation, announced the filing of a PRE 14A preliminary proxy statement with the SEC, scheduling its 2024 annual meeting of stockholders for December 27, 2024. The meeting will be held virtually, with stockholders unable to attend physically. The Board of Directors extended an invitation to stockholders to attend and vote on several proposals, including the election of three Class II directors, amendments to the 2022 Omnibus Incentive Plan, executive compensation, and the issuance of common stock upon conversion of Series B Convertible Preferred Stock and exercise of warrants. The meeting will also cover the ratification of M&K CPAs, PLLC as the company's independent auditors for the fiscal year ending December 31, 2024. The proxy statement was first sent to stockholders on or about November 11, 2024, and includes instructions for voting online, by mail, fax, or telephone. The Board unanimously recommends voting for all proposed items.
180 Life Sciences Corp., a Delaware corporation, announced the filing of a PRE 14A preliminary proxy statement with the SEC, scheduling its 2024 annual meeting of stockholders for December 27, 2024. The meeting will be held virtually, with stockholders unable to attend physically. The Board of Directors extended an invitation to stockholders to attend and vote on several proposals, including the election of three Class II directors, amendments to the 2022 Omnibus Incentive Plan, executive compensation, and the issuance of common stock upon conversion of Series B Convertible Preferred Stock and exercise of warrants. The meeting will also cover the ratification of M&K CPAs, PLLC as the company's independent auditors for the fiscal year ending December 31, 2024. The proxy statement was first sent to stockholders on or about November 11, 2024, and includes instructions for voting online, by mail, fax, or telephone. The Board unanimously recommends voting for all proposed items.
180 Life Sciences Corp.，一家特拉华州公司，宣布向SEC提交了一份PRE 14A初步代理声明，将其2024年股东年会定于2024年12月27日举行。会议将以虚拟形式进行，股东无法亲自参加。董事会邀请股东参加并对多项提案进行投票，包括选举三名Class II董事，修改2022年份股权激励计划，执行薪酬，以及根据B系列可转换优先股和权证行使发行普通股。会议还将涉及对M&k会计师事务所作为公司截至2024年12月31日财政年度的独立审计师的批准。这份代理声明最早于2024年11月11日左右发送给股东，并包括在线投票、邮寄、传真或电话投票的说明。董事会一致建议投票支持所有提议事项。
180 Life Sciences Corp.，一家特拉华州公司，宣布向SEC提交了一份PRE 14A初步代理声明，将其2024年股东年会定于2024年12月27日举行。会议将以虚拟形式进行，股东无法亲自参加。董事会邀请股东参加并对多项提案进行投票，包括选举三名Class II董事，修改2022年份股权激励计划，执行薪酬，以及根据B系列可转换优先股和权证行使发行普通股。会议还将涉及对M&k会计师事务所作为公司截至2024年12月31日财政年度的独立审计师的批准。这份代理声明最早于2024年11月11日左右发送给股东，并包括在线投票、邮寄、传真或电话投票的说明。董事会一致建议投票支持所有提议事项。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间